Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE
    • Publication Information:
      Publication: <2005->: Amsterdam : Elsevier Scientific Publishers
      Original Publication: Boca Raton, Fla. : CRC Press, 1983-
    • Subject Terms:
      Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell*/complications ; Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2*/antagonists & inhibitors ; Protein Kinase Inhibitors*/therapeutic use ; Protein Kinase Inhibitors*/adverse effects ; Infections*/etiology ; Infections*/epidemiology ; Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use; Humans ; Sulfonamides/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Clinical Trials as Topic
    • Abstract:
      Bruton tyrosine kinase inhibitors (BTKi) and the BCL-2 inhibitor venetoclax have significantly improved the prognosis of patients with chronic lymphocytic leukemia (CLL). However, the incidence of severe infections in patients receiving these agents needs to be better understood. Our review aimed to provide an overview of grade ≥3 infections in patients with CLL who received BTKi and venetoclax-based therapy in prospective trials. Infection rates were influenced by the age of patients and the duration of follow-up. For treatment-naive (TN) patients receiving BTKi, infection rates ranged between 11.4 % and 27.4 % and were close to 30 % in relapsed/refractory (R/R) patients. TN and R/R patients receiving fixed-duration venetoclax-based treatments showed variable rates, with maximum values around 20 %. Opportunistic and fatal infections were uncommon. In conclusion, infections remain a concern in patients with CLL receiving targeted agents. A better definition of factors increasing infection vulnerability could help identify those patients who require infection prophylaxis.
      Competing Interests: Declaration of Competing Interest F.R.M.: Funding for research and educational projects from Abbvie, Takeda, Janssen. Member of Advisory Board for AbbVie, Beigene, AstraZeneca, Janssen. A.M.F.: Member of Advisory Board for Janssen, Beigene, AstraZeneca, Abbvie. A.V.: Member of Advisory Board for AbbVie, Beigene, AstraZeneca, Janssen, CSL Behring, Takeda. C.V.: Consultancy fees from Abbvie and Astra Zeneca. M.B.: speaker/advisor fees from MSD, BioMérieux, Gilead, AstraZeneca, Advanz, and Pfizer, all outside the submitted work. C.O.: None. E.Z.: None. M.M.: grant from Gilead paid to the Institution; speaker/advisor fees from Allovir, BioMérieux, Gilead, Janssen, Moderna, Mundipharma and Pfizer, all outside the submitted work.
      (Copyright © 2024. Published by Elsevier B.V.)
    • Contributed Indexing:
      Keywords: BCL2 inhibitors; Chronic lymphocytic leukemia; Infections, BTK inhibitors; Treatment
    • Accession Number:
      EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
      0 (Proto-Oncogene Proteins c-bcl-2)
      EC 2.7.10.2 (BTK protein, human)
      0 (Protein Kinase Inhibitors)
      0 (BCL2 protein, human)
      N54AIC43PW (venetoclax)
      0 (Bridged Bicyclo Compounds, Heterocyclic)
      0 (Sulfonamides)
      0 (Antineoplastic Agents)
    • Publication Date:
      Date Created: 20240616 Date Completed: 20240816 Latest Revision: 20240822
    • Publication Date:
      20240823
    • Accession Number:
      10.1016/j.critrevonc.2024.104408
    • Accession Number:
      38880368